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Abstract
Background: There are no risk scores available for predicting heart failure in Type 2 diabetes
mellitus (T2DM). Based on the Hong Kong Diabetes Registry, this study aimed to develop and
validate a risk score for predicting heart failure that needs hospitalisation in T2DM.
Methods: 7067 Hong Kong Chinese diabetes patients without history of heart failure, and without
history and clinical evidence of coronary heart disease at baseline were analyzed. The subjects have
been followed up for a median period of 5.5 years. Data were randomly and evenly assigned to a
training dataset and a test dataset. Sex-stratified Cox proportional hazard regression was used to
obtain predictors of HF-related hospitalization in the training dataset. Calibration was assessed
using Hosmer-Lemeshow test and discrimination was examined using the area under receiver's
operating characteristic curve (aROC) in the test dataset.
Results:  During the follow-up, 274 patients developed heart failure event/s that needed
hospitalisation. Age, body mass index (BMI), spot urinary albumin to creatinine ratio (ACR), HbA1c,
blood haemoglobin (Hb) at baseline and coronary heart disease during follow-up were predictors
of HF-related hospitalization in the training dataset. HF-related hospitalization risk score = 0.0709
× age (year) + 0.0627 × BMI (kg/m2) + 0.1363 × HbA1c(%) + 0.9915 × Log10(1+ACR) (mg/mmol) -
0.3606 × Blood Hb(g/dL) + 0.8161 × CHD during follow-up (1 if yes). The 5-year probability of
heart failure = 1-S0(5)EXP{0.9744 × (Risk Score - 2.3961)}. Where S0(5) = 0.9888 if male and 0.9809 if female.
The predicted and observed 5-year probabilities of HF-related hospitalization were similar (p >
0.20) and the adjusted aROC was 0.920 for 5 years of follow-up.
Conclusion: The risk score had adequate performance. Further validations in other cohorts of
patients with T2DM are needed before clinical use.
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Background
Besides coronary heart disease (CHD), diabetes is another
major cause for hospital admissions due to heart failure
(HF), which contributes to major morbidity and prema-
ture mortality in people with diabetes [1]. Subjects with
Type 2 diabetes and impaired glucose regulation have 2.8-
fold and 1.7-fold risk of developing HF respectively, when
compared to individuals with normoglycemia [2]. The
Framingham Study [3] and the United Kingdom Prospec-
tive Diabetes Study (UKPDS) developed risk scores or
engines to predict CHD-related events [4] and stroke [5].
Based on the Hong Kong Diabetes Registry, our group has
developed and validated risk scores for predicting end-
stage renal disease [6,7], stroke [8], coronary heart disease
[9] and all-cause mortality [10]. These risk equations may
enable risk stratification for more effective preventive
strategies in Chinese patients with type 2 diabetes. Not-
withstanding the importance of HF in type 2 diabetes, the
predictors for HF have not been fully explored.
The Hong Kong Diabetes Registry was established in 1995
as a quality assurance and continuous improvement tool
with particular focus on risk stratification, treatment to
targets and patient empowerment. In the present analysis,
we aimed to develop and validate a risk score for predict-
ing HF that needed hospitalization.
Methods
Subjects
The Prince of Wales Hospital is a regional hospital which
covers a catchment area of 1.2 million residents. The
Hong Kong Diabetes Registry was established in 1995 and
enrols 30–50 ambulatory diabetic patients each week. The
referral sources included general practitioners, commu-
nity and other specialty clinics as well as patients dis-
charged from hospitals. Enrolled patients with hospital
admissions within 6–8 weeks prior to assessment
accounted for less than 10% of all referrals. The 4-hour
assessment of complications and risk factors was per-
formed on an outpatient basis, modified from the Euro-
pean DIABCARE protocol [11]. The study was approved
by the Chinese University of Hong Kong Clinical Research
Ethics Committee and written informed consent was
obtained from all patients. From 1995 to 2005, 7920 dia-
betic patients were enrolled in this Registry. Among them,
332 with Type 1 diabetes defined as acute presentation
with diabetic ketoacidosis, heavy ketonuria (>3+) or con-
tinuous requirement of insulin within 1 year of diagnosis,
and 5 with uncertain type 1 diabetes status, were excluded
from the analysis. In addition, 49 with non-Chinese or
unknown nationality were excluded. In line with the
UKPDS CHD risk engine [4] and our CHD risk score [9],
467 patients were also excluded due to past history of
CHD or HF. A total of 7067 Chinese patients with type 2
diabetes who were free of past history of HF and CHD at
enrolment were included in this analysis.
Clinical outcomes
Clinical endpoints included hospital discharge diagnoses
and mortality recorded before or on 30th July 2005 were
recorded or otherwise censored on 30th July 2005. Details
of hospital admissions were retrieved from the Hong
Kong Hospital Authority Central Computer System. The
latter records admissions to all public hospitals, which
account for about 95% of hospital bed-days due to the
heavily subsidized health care system in Hong Kong.
These databases including the Hong Kong Death Registry
were matched by a unique identification number, the
Hong Kong Identity Card number, which is compulsory
for all residents in Hong Kong. Principal hospital dis-
charge diagnoses coded by the International Classifica-
tion of Diseases Ninth Revision were used to identify HF
that needed hospitalisation (Code 428). The diagnosis of
HF was consistent with the recommended guidelines [12].
Follow-up time was calculated as the time from enrol-
ment to the first hospitalization for HF, death or 30th July
2005.
Clinical measurements
Details of assessment methods and definitions have been
previously described [6,8-10,13]. On the day of assess-
ment, patients attended the centre after 8 hours of fasting
and underwent anthropometric measurements and labo-
ratory investigations. Apart from documentation of
demographic data and clinical assessment of complica-
tions, fasting blood samples were taken for measurement
of plasma glucose, glycosylated haemoglobin (HbA1c),
lipid profile (total cholesterol, high density lipoprotein
cholesterol and triglycerides, calculated low density lipo-
protein cholesterol, renal and liver functions. A sterile,
random spot urine sample was used to measure albumin
creatinine ratio (ACR). Peripheral arterial disease was
defined by lower limb amputation, the absence of foot
pulses on palpation, confirmed by an ankle:brachial ratio
≤0.90 as measured by Doppler ultrasound examination,
or history of revascularization for peripheral arterial dis-
ease. This study used the abbreviated Modification of Diet
in Renal Disease (MDRD) formula re-calibrated for Chi-
nese [14] to estimate glomerular filtration rate (eGFR)
expressed in ml min-1 1.73 m-2: eGFR = 186 × [SCR ×
0.011] -1.154 × [age] -0.203 × [0.742 if female] × 1.233, where
SCR is serum creatinine expressed as µmol/l (original mg/
dL converted to µmol/l) and 1.233 is the adjusting coeffi-
cient for Chinese ethnicity. Laboratory assays have also
been described previously [6].
Statistical analyses
The Statistical Analysis System (Release 9.10) was used to
perform the statistical analysis (SAS Institute Inc., Cary,Cardiovascular Diabetology 2008, 7:9 http://www.cardiab.com/content/7/1/9
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USA). Split-half validation was used to develop the risk
score. The dataset was randomly divided into two datasets
using a computer-generated random number: the training
dataset for model development and the test dataset for
validation of the developed HF risk score. In the training
dataset, Cox proportional regression analysis with the
backward algorithm (p < 0.05 for stay) was used to select
predictors of HF. The candidate baseline variables for
inclusion in the final model included age, sex, current and
ex smoker status, duration of diabetes, systolic blood pres-
sure, glycated haemoglobin (HbA1c), body mass index
(BMI), blood haemoglobin (Hb), white blood cell count,
high density lipoprotein cholesterol, low density lipopro-
tein cholesterol, triglyceride, non-high density lipoprotein
cholesterol, spot urinary ACR, eGFR, sensory neuropathy,
retinopathy, peripheral arterial disease, history of stroke,
and drug use variables (lipid-lowering drugs and angi-
otensin-converting enzyme (ACE) inhibitors or angi-
otensin II receptor blockers (ARB), diet treatment, oral
anti-diabetic drugs, other antihypertensive drugs, and
insulin at enrolment). As CHD is an important risk pre-
dictor of HF [15], we added an additional variable that
recorded CHD events during follow-up period [9] to
improve the predicting ability of the HF risk score. Propor-
tional hazards assumption and functional form were
checked using Supremum test [16].
Construction of risk scores and probability equations
from Cox models have been described previously [8,9].
The shrinkage factor was calculated using (LR-p)/LR,
where LR denotes the likelihood ratio χ2  and p the
number of the predictors in the final model (below 0.85
raises concern of over-fitting) [17].
Validation of the risk score was performed using the test
dataset. Calibration was checked using the Hosmer and
Lemeshow test [10]. Overall discrimination was checked
by C index as calculated by Pencina's method [18]. The 5-
year discrimination as indicated by the area under receiver
operating characteristic curve, as well as the 5-year sensi-
tivity and specificity were calculated using Chambless'
method [19]. A p value < 0.05 was considered to be statis-
tically significant.
Results
Characteristics of study population
At enrolment, the median age of the cohort was 57 years
(interquartile range, IQR: 46–67 years) and the median
duration of diabetes was 5 (IQR: 1–11) years. During a
median follow-up period of 5.52 years (IQR: 2.90–7.87
years), 3.32% (n = 274) of patients had HF that needed
hospitalisation, giving an incident rate of 7.17 (95% CI:
6.33–8.02) per 1000 person-years. During the follow-up
period, 681 patients died. Other population characteris-
tics are listed in Table 1. In the training dataset, compared
to patients without hospitalisation for HF, those with hos-
pitalisation for HF had older age (median/IQR 69/13 vs.
56/20 years, p < 0.0001), higher HbA1c (7.8/2.6 vs. 6.7/
2.1%, p < 0.0001), higher ACR (52.5/230.7 vs. 1.9/8.4
mg/mmol, p < 0.0001), lower blood Hb (12.5/2.6 vs.
13.9/2.1 g/dL, p < 0.0001) and longer duration of diabe-
tes (10/11 vs. 5/9 years, p < 0.0001) but had similar BMI
(24.7/4.9 vs. 24.7/4.8 kg/m2, p = 0.5021).
Predicting models
In the training dataset, age, sex, BMI, HbA1c, Log10
(ACR+1) and blood Hb at baseline and CHD event during
follow-up were selected by the model as predictors for HF-
related hospitalisation. The functional forms of age, BMI,
HbA1c, Log10 (ACR+1) and Hb seem adequate (p > 0.40).
All the predictors apart from sex (p < 0.0001) did not vio-
late the proportional hazards assumption (p > 0.20). To
correct for violation of proportional hazards assumption
in sex (p = 0.0080), sex-stratified Cox model was used to
derive β and hazard ratio estimates of age, BMI, HbA1c,
Log10 (ACR+1) and blood Hb at baseline and CHD during
follow-up. Their hazard ratios (both univariate and multi-
variate analyses), β coefficients and 95% confidence inter-
vals (CI) are listed in Table 2. Over-fitting of the final
predicting model is, if any, very small (the shrinkage =
0.9744).
Based on the values of β coefficients, the risk score and 5-
year probability of HF that needs hospitalisation are con-
structed as follows:
HF-related hospitalization risk score = 0.0709 × age (year)
+ 0.0627 × BMI (kg/m2) + 0.1363 × HbA1c (%) + 0.9915 ×
Log10(1+ACR) (mg/mmol) - 0.3606 × Blood Hb (g/dL) +
0.8161 × CHD during follow-up (1 if yes).
The 5-year probability of heart failure = 1-S0(5)EXP{0.9744 ×
(Risk Score - 2.3961)}, where S0(5) = 0.9888 if male and 0.9809
if female.
Validation of risk equations
In the test dataset, the predicted probability of HF-related
hospitalisation over 5 years of follow-up was not signifi-
cantly different from the observed probability of HF-
related hospitalisation probability (p > 0.20) (Figure 1).
The overall C index (for overall discrimination) was 0.853
(95% CI: 0.819–0.886). The follow-up time and censor-
ing status adjusted aROC for 5 years of follow-up was
0.920. Using the cut-off point of ≥3.4683 for the risk
score, the sensitivity was 90.5% and the specificity was
75.6%. If the cut-off point of 4.5334 was used, the sensi-
tivity decreased to 71.1% while the specificity increased to
90.4%. Sensitivities and specificities of other cut-off
points are listed in Table 3.Cardiovascular Diabetology 2008, 7:9 http://www.cardiab.com/content/7/1/9
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Discussion
In this analysis, we demonstrated that HF that needed
hospitalisation can be predicted with good accuracy in
type 2 diabetes. Using 7 commonly collected variables:
age, sex, BMI, HbA1c, ACR and blood Hb, the risk score
can provide absolute risks of hospitalisation for HF,
which depends on whether CHD event/s occurs or not in
a 5-year period. The risk score has achieved an excellent
discriminatory power of 0.920 for predicting hospitalisa-
tion due to HF over a 5-year period in type 2 diabetic
patients while maintaining adequate calibration.
The discrimination of a risk score determines the efficacy
and thus usefulness of a risk score. Several risk scores have
been published for predicting hard CHD events, i.e. non-
fatal myocardial infarction and fatal CHD events, in both
general and type 2 diabetic populations. The Framingham
CHD risk score has an C-statistics of 0.79 for men and
0.83 for women in their original population and 0.63–
0.75 for men and 0.66–0.83 for women in other USA pop-
ulations [20]. Liu et al [21]validated the Framingham risk
score in a general Chinese population and the re-cali-
brated risk score had an aROC of 0.71 for Chinese men
and 0.74 for Chinese women. The UKPDS risk engine for
hard CHD endpoints did not report any measures of dis-
crimination in the original report [4]. A validation study
in a UK type 2 diabetic population by Guzder et al [22]
reported that the UKPDS CHD risk engine had a discrim-
ination of 0.67 for C-statistics. Donnan et al [23] devel-
oped a risk score for major CHD in type 2 diabetes
population with a discrimination score of 0.71 in the orig-
inal dataset and 0.69 in an independent dataset. Another
Table 1: Baseline clinical and biochemical characteristics of 7074 Chinese Type 2 diabetic patients without clinical evidence of 
coronary heart disease and heart failure at enrollment during 5.52 years of follow-up in the training dataset and the test dataset
Training dataset (n = 3456) Test dataset (n = 3611)
median or % IQR* median or % IQR*
Male Gender 45.2% 45.6%
Smoking status
Current smoker 20.4% 20.7%
Ex smoker 13.1% 13.8%
Age (year) 57 21 57 21
Body mass index (kg/m2) 24.6 4.8 24.7 5.0
Years of diagnosed diabetes 5 10 5 9
Systolic BP (mmHg) 134 27 134 28
Diastolic BP (mmHg) 76 13 76 15
HbA1c (%) 7.3 2.2 7.4 2.2
Blood haemoglobin (g/L) 13.8 2.1 13.8 2.2
White blood cell count (109/counts/L) 7.0 2.4 7.0 2.4
Spot urinary albumin creatinine ratio (mg/mmol) 2.0 10.1 2.0 10.0
eGFR (ml min-1 1.73 m-2) ξ 104.9 43.0 104.9 43.5
LDL-C (mmol/l) 3.13 1.24 3.11 1.29
HDL-C (mmol/l) 1.24 0.45 1.25 0.45
Triglyceride (mmol/L) 1.37 1.08 1.39 1.12
Non-HDL cholesterol (mmol/L) 3.87 1.40 3.87 1.43
Drug use at baseline
On diet treatment 10.2% 9.9%
Use of oral anti-diabetic drugs 61.0% 60.6%
Use of anti-hypertensive drugs 34.1% 33.3%
Use of insulin 17.5% 17.4%
Use of LLD§ 11.6% 13.2%
Use of ACEI or ARB¶ 20.4% 20.1%
Complications at baseline
Retinopathy 25.4% 27.4%
Sensory neuropathy 26.0% 25.7%
Peripheral arterial disease 5.8% 5.9%
History of stroke 3.6% 4.4%
Complications during follow-up
Coronary heart disease before heart failure during follow-up 4.4% 4.4%
Heart failure hospitalisation during follow-up 3.8% 4.0%
Death during follow-up 9.4% 9.9%
*, Median (IQR = interquartile range); ξ, eGFR = estimated glomerular filtration rate; §, LLD, lipid lowering drugs; ¶, ACEI, Angiotensin-converting 
enzyme inhibitors and ARB for angiotensin II receptor blockers.Cardiovascular Diabetology 2008, 7:9 http://www.cardiab.com/content/7/1/9
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risk score which predicted cardiovascular events and mor-
tality using clinical predictors and baseline dobutamine
stress echocardiography reported C-statistics values of
0.60 and 0.64 respectively [24]. Thus, a discriminatory
power of C index 0.85 and aROC 0.92 of the current HF-
related hospitalisation risk score indicates an excellent
performance in distinguishing between those who would
need hospitalisation for HF from their counterparts who
would not. Comparing this risk score with other risk
scores that were derived from the same cohort, the risk
score has better discriminatory power than CHD (aROC:
0.74) [9], stroke (aROC: 0.77) [8] and all-cause mortality
(aROC: 0.85) risk scores [10] but poorer discriminatory
power than end stage renal disease risk score (aROC >
0.94)[6,7]. Similarly, the calibration is also adequate, bet-
ter than the CHD risk score[9]but poorer than the all-
cause mortality risk score [10].
Besides the CHD status on follow-up, the risk scores
included as few as 6 baseline variables: age, BMI, HbA1c,
ACR, blood Hb and sex. Most of these parameters have
been verified to be associated with HF in other studies.
HbA1c has been repeatedly found to be associated with
increased risk of HF [1,25]. Low hematocrit and Hb levels
have recently emerged as a major promoter of cardiovas-
cular morbidity and mortality [26]. In agreement with
Horwich et al [27] who reported association of anemia
with early mortality in patients with advanced HF, we
found that blood Hb had a strong independent predictive
effect in the present cohort. Low Hb level can cause HF via
many mechanisms including tissue hypoxia and left ven-
tricular failure [28]. Several studies have now confirmed
the strong risk association between albuminuria and HF
in patients with type 2 diabetes [29-31]. Hockensmith et
al [30] reported that baseline albuminuria was independ-
ently associated with 5.4 fold increased odds ratio of hos-
pitalizations due to HF (95% CI: 2.3–12.5). In the
Angiotensin II Antagonist Losartan Trial which recruited
1513 type 2 diabetic patients with nephropathy, high
baseline albuminuria was associated with a 2.70-fold risk
Table 2: Parameter estimates of the risk score for heart failure hospitalisation in the training dataset.
Univariate Analysis Multivariate Analysis
Variables† Hazard ratio (95% CI) P value Estimates of β values S.E.M Hazard ratio (95% CI) P value
Variables used in the predicting model
Age, per year 1.10(1.08–1.12) <.0001 0.0709 0.0107 1.07(1.05–1.10) <.0001
Body mass index, per kg/m2 1.01(0.97–1.05) 0.6568 0.0627 0.0286 1.07(1.01–1.13) 0.0282
Glycated haemoglobin, per % 1.16(1.07–1.25) 0.0003 0.1363 0.0550 1.15(1.03–1.28) 0.0132
Log10(1+spot urinary albumin to creatinine 
ratio, per mg/mmol)
4.50(3.65–5.54) <.0001 0.9915 0.1409 2.70(2.32–3.55) <.0001
Blood haemoglobin, per g/dL 0.61(0.55–0.68) <.0001 -0.3606 0.0684 0.70(0.61–0.80) 0.0001
Coronary heart disease during follow-up (1. 
yes, 0. no)
3.61(2.24–5.81) <.0001 0.8161 0.2675 2.26(1.26–4.05) 0.0061
Variables not used in the predicting model
Duration of diabetes, per year 1.07(1.05–1.09) <.0001 Not selected
Glomerular filtration rate, per ml min-1 1.73 m-
2
0.97(0.96–0.97) <.0001 Not selected
Systolic blood pressure, per mmHg 1.03(1.02–1.04) <.0001 Not selected
Diastolic blood pressure, per mmHg 1.01(0.99–1.02) 0.5640 Not selected
Low density lipoprotein cholesterol, per 
mmol/L
1.12(0.94–1.33) 0.2155 Not selected
High density lipoprotein cholesterol, per 
mmol/L
0.80(0.48–1.34) 0.3976 Not selected
Triglyceride, per mmol/L 1.04 (0.96–1.12) 0.3665 Not selected
Smoking status Not selected
Current smokers 0.62(0.37–1.02) 0.0592
Ex-smokers 1.96(1.28–3.01) 0.0020
Never 1.0
Use of oral anti-diabetic drugs at baseline 1.04(0.73–1.47) 0.8471 Not selected
Use of anti-hypertensive drugs at baseline 3.98(2.79–5.67) <.0001 Not selected
Use of LLD at baseline 1.88(1.16–3.09) 0.0112 Not selected
Use of ACEI or ARB at baseline 2.44(1.66–3.59) <.0001 Not selected
Use of insulin at baseline 3.59(2.52–5.10) <.0001 Not selected
†, Sex-stratified Cox model was used to obtain estimates of β values and hazard rato of predctors for heart failure. χ2 test for likelihood ratio test 
= 234.60, Degree of freedom = 6, p < 0.0001 and the shrinkage of the model is = (234.60-6)/274.66 = 0.9744; Not selected indiates not selected by 
the backward algorithm at the significant levelt of 0.05.
CI, confidence interval; LLD, lipid lowering drugs; ACEI, Angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockersCardiovascular Diabetology 2008, 7:9 http://www.cardiab.com/content/7/1/9
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for HF compared with patients with low levels of albu-
minuria and that reduction of ACR at 6 months post treat-
ment including the use of ARB predicted reduced risk of
new onset of HF [32]. A study reported that BMI was not
a significant predictor for mortality in patients with
advanced HF [33]. In our analysis, BMI was also not a sig-
nificant predictor of HF on univariable analysis but
became significant after adjustment for Hb. Close associ-
ations between high blood Hb, hyperviscosity syndrome
and obesity [34] may mask the true increased risk of high
BMI if blood Hb was not adjusted.
The risk score used future CHD events as a "predictor".
The future event is unknown at the time of prediction.
Nevertheless, the CHD absolute risk can be estimated
using the CHD risk score developed from the same
cohort[9], using age, sex, current smoking status, duration
of diabetes, non high density lipoprotein cholesterol, ACR
and eGFR. In the UKPDS, both CHD and stroke risk
engines were used in the case mortality risk engine to esti-
mate the absolute risk of case mortality of patients who
subsequently developed CHD or stroke event [35]. Simi-
larly, our CHD risk score can also be used in the risk score
to estimate the absolute risk of hospitalization for HF.
Limitations
First, similar to another study [29], we used the definition
of hospitalisation for HF rather than HF itself. The possi-
bility underestimating severe HF incidence using this def-
inition should be very small since Hong Kong
Government maintains a heavily subsidised health care
system and severe HF without being hospitalised are most
unlikely. Second, although the registry is not population-
based, due to the lack of a comprehensive health insur-
ance policy and integrated primary health care system in
Hong Kong, majority of patients in patients with chronic
diseases such as diabetes and heart disease are managed in
public hospitals. In 2000, Department of Health of Hong
Table 3: Sensitivity, specificity, positive predictive values at selected risk scores and the probability of heart failure over 5 years of 
follow-up in the test dataset
Risk score cutoff point* Predicted probability of heart failure Sensitivity Specificity Positive predictive value Negative predictive value
Women Men
2.5606 0.0131 0.0129 0.980 0.571 0.429 0.086
3.0776 0.0216 0.0213 0.954 0.685 0.315 0.111
3.3153 0.0272 0.0267 0.929 0.726 0.274 0.122
3.4683† 0.0315 0.0310 0.905 0.756 0.244 0.132
3.5859 0.0353 0.0346 0.896 0.777 0.223 0.142
3.6385 0.0371 0.0364 0.883 0.786 0.214 0.145
3.9032 0.0477 0.0469 0.873 0.827 0.173 0.172
3.9644 0.0506 0.0497 0.851 0.837 0.163 0.177
4.1012 0.0576 0.0566 0.831 0.857 0.143 0.193
4.2309 0.0651 0.0640 0.821 0.877 0.123 0.216
4.3201 0.0708 0.0696 0.786 0.887 0.113 0.222
4.4208 0.0778 0.0765 0.727 0.894 0.106 0.220
4.5334† 0.0864 0.0849 0.711 0.904 0.096 0.234
4.6189 0.0936 0.0920 0.698 0.914 0.086 0.250
4.7414 0.1048 0.1030 0.662 0.923 0.077 0.261
4.8633 0.1172 0.1152 0.607 0.931 0.069 0.266
5.0962 0.1448 0.1424 0.551 0.950 0.050 0.311
5.4119 0.1916 0.1886 0.437 0.966 0.034 0.345
*, Calculated using the risk score equation; **, Calculated using the 5-year heart failure probability; †, The suggested cutoff points.
The predicted probability of heart failure that needed hospi- talisation versus the observed probability over 5 years of fol- low-up in the test dataset Figure 1
The predicted probability of heart failure that 
needed hospitalisation versus the observed probabil-
ity over 5 years of follow-up in the test dataset.Cardiovascular Diabetology 2008, 7:9 http://www.cardiab.com/content/7/1/9
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Kong conducted a survey and reported that over 90% of
patients diagnosed with diabetes were managed in the
public health sector [10]. Third, our cohort of type 2 dia-
betic patients had a wide range of disease duration which
may theoretically widen the 95% CI of parameter estima-
tions. On the other hand, it is the heterogeneity that
extends usefulness of this risk score from predicting HF
hospitalization at diagnosis to predicting HF hospitalisa-
tion during long-term care of patients with type 2 diabe-
tes, i.e. the risk score can be used periodically during
chronic care management.
Conclusion and Implications
To our knowledge, this is the first risk score developed to
predict HF events in a type 2 diabetic cohort. Given the ris-
ing prevalence of type 2 diabetes [36] and the high risk of
morbidity and mortality of HF, especially in patients with
diabetes [1], a risk score with such excellent performance,
should enable clinicians to identify high risk subjects for
intensive monitoring and treatment. Hence, validation of
the risk score in other populations will be of public health
importance.
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